ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma

a randomized phase 2 study

Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis E. Fayad, Nancy L. Bartlett, Douglas Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham H. Wilson, Andre Goy, Anas Younes, Hun Ju Lee

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)e65-e67
JournalHaematologica
Volume104
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Hodgkin Disease
Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Strati, P., Fanale, M. A., Oki, Y., Turturro, F., Fayad, L. E., Bartlett, N. L., ... Lee, H. J. (2019). ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica, 104(2), e65-e67. https://doi.org/10.3324/haematol.2018.199844

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma : a randomized phase 2 study. / Strati, Paolo; Fanale, Michelle A.; Oki, Yasuhiro; Turturro, Francesco; Fayad, Luis E.; Bartlett, Nancy L.; Gladstone, Douglas; Kasamon, Yvette L.; Portlock, Carol S.; Wilson, Wyndham H.; Goy, Andre; Younes, Anas; Lee, Hun Ju.

In: Haematologica, Vol. 104, No. 2, 01.02.2019, p. e65-e67.

Research output: Contribution to journalLetter

Strati, P, Fanale, MA, Oki, Y, Turturro, F, Fayad, LE, Bartlett, NL, Gladstone, D, Kasamon, YL, Portlock, CS, Wilson, WH, Goy, A, Younes, A & Lee, HJ 2019, 'ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study', Haematologica, vol. 104, no. 2, pp. e65-e67. https://doi.org/10.3324/haematol.2018.199844
Strati, Paolo ; Fanale, Michelle A. ; Oki, Yasuhiro ; Turturro, Francesco ; Fayad, Luis E. ; Bartlett, Nancy L. ; Gladstone, Douglas ; Kasamon, Yvette L. ; Portlock, Carol S. ; Wilson, Wyndham H. ; Goy, Andre ; Younes, Anas ; Lee, Hun Ju. / ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma : a randomized phase 2 study. In: Haematologica. 2019 ; Vol. 104, No. 2. pp. e65-e67.
@article{da66f4413fe540a69155f9d39fecedca,
title = "ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study",
author = "Paolo Strati and Fanale, {Michelle A.} and Yasuhiro Oki and Francesco Turturro and Fayad, {Luis E.} and Bartlett, {Nancy L.} and Douglas Gladstone and Kasamon, {Yvette L.} and Portlock, {Carol S.} and Wilson, {Wyndham H.} and Andre Goy and Anas Younes and Lee, {Hun Ju}",
year = "2019",
month = "2",
day = "1",
doi = "10.3324/haematol.2018.199844",
language = "English (US)",
volume = "104",
pages = "e65--e67",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "2",

}

TY - JOUR

T1 - ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma

T2 - a randomized phase 2 study

AU - Strati, Paolo

AU - Fanale, Michelle A.

AU - Oki, Yasuhiro

AU - Turturro, Francesco

AU - Fayad, Luis E.

AU - Bartlett, Nancy L.

AU - Gladstone, Douglas

AU - Kasamon, Yvette L.

AU - Portlock, Carol S.

AU - Wilson, Wyndham H.

AU - Goy, Andre

AU - Younes, Anas

AU - Lee, Hun Ju

PY - 2019/2/1

Y1 - 2019/2/1

UR - http://www.scopus.com/inward/record.url?scp=85060939152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060939152&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.199844

DO - 10.3324/haematol.2018.199844

M3 - Letter

VL - 104

SP - e65-e67

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -